HC Wainwright Issues Positive Forecast for Verve Therapeutics (NASDAQ:VERV) Stock Price

Verve Therapeutics (NASDAQ:VERV - Free Report) had its price target raised by HC Wainwright from $15.00 to $25.00 in a research report released on Monday, MarketBeat Ratings reports. They currently have a buy rating on the stock.

Other research analysts have also recently issued research reports about the company. Guggenheim restated a "buy" rating on shares of Verve Therapeutics in a research report on Tuesday, March 25th. Royal Bank of Canada lowered their price target on shares of Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating for the company in a report on Tuesday, March 4th. Finally, William Blair reiterated an "outperform" rating on shares of Verve Therapeutics in a research note on Friday, February 21st. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $25.75.

Verve Therapeutics Trading Up 1.8 %

Shares of VERV traded up $0.08 during mid-day trading on Monday, hitting $4.59. The company's stock had a trading volume of 2,590,118 shares, compared to its average volume of 1,707,735. Verve Therapeutics has a 1-year low of $2.86 and a 1-year high of $9.31. The firm has a market capitalization of $407.57 million, a P/E ratio of -1.87 and a beta of 1.86. The firm has a 50-day simple moving average of $5.63 and a 200 day simple moving average of $5.91.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.72) by $0.14. The company had revenue of $13.08 million during the quarter, compared to analysts' expectations of $3.94 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. As a group, sell-side analysts predict that Verve Therapeutics will post -2.49 EPS for the current fiscal year.

Institutional Investors Weigh In On Verve Therapeutics

Several large investors have recently made changes to their positions in the business. GAMMA Investing LLC lifted its holdings in shares of Verve Therapeutics by 189.7% during the 4th quarter. GAMMA Investing LLC now owns 6,054 shares of the company's stock valued at $34,000 after acquiring an additional 3,964 shares in the last quarter. KFG Wealth Management LLC purchased a new position in Verve Therapeutics in the first quarter valued at about $46,000. IFP Advisors Inc lifted its stake in shares of Verve Therapeutics by 823,700.0% during the fourth quarter. IFP Advisors Inc now owns 8,238 shares of the company's stock worth $47,000 after purchasing an additional 8,237 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of Verve Therapeutics in the fourth quarter worth about $50,000. Finally, Impact Partnership Wealth LLC acquired a new stake in shares of Verve Therapeutics in the fourth quarter valued at about $70,000. Institutional investors and hedge funds own 97.11% of the company's stock.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.